Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
Cagrilintide
Batch #
N/A
Formula
C194H312N54O59S2
Mol Wt
4408.258 g/mol
CAS
1415456-99-3
Latest
ISO 17025
8× Testing
99.7%
Purity
VariantCagrilintide
COA ##13138
Labeled10mg
Validation KeyAXISBIOTECH
Tested05/12/26
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.7%
✓
Net Peptide Content - 10mg
✓
Identity (HPLC) - Cagrilintide
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - >99%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
Cagrilintide at 2.4 mg for the treatment of obesity: a randomised, placebo-controlled and active-comparator-controlled phase 2 trial
02
CagriSema versus semaglutide, cagrilintide, and placebo in adults with overweight and obesity: a randomised, dose-finding phase 2 trial
03
Synergistic effects of semaglutide and cagrilintide on appetite, energy intake, body weight and glucose tolerance in lean and obese rats
04
Pharmacokinetics, pharmacodynamics, and safety of cagrilintide, a novel long-acting amylin analogue
05
Amylin-based peptide therapeutics in obesity: mechanisms and clinical developments
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
